IA-05592 / ILAb - LARVOL DELTA

IA-05592: A breakthrough oral PD-L1 inhibitor with exceptional anti-tumor efficacy and immune activation potential (AACR 2025) - "These findings position IA-05592 as a promising candidate for next-generation cancer immunotherapy, offering a unique mechanism of action and robust preclinical anti-tumor efficacy comparable to anti-PD-L1 antibodies. Ongoing studies aim to advance IA-05592 as a key component of all-oral cancer immunotherapy regimens."

Clinical • IO biomarker • Head and Neck Cancer • Oncology • Oral Cancer • Solid Tumor